Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. Karyopharm is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.

Type
Subsidiary
Parent Company
Biogen
HQ
Newton, US
Founded
2008
Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, US
Report incorrect company information

Key People/Management at Karyopharm Therapeutics

Michael Kauffman

Michael Kauffman

Chief Executive Officer &Board of Directors
John McCartney

John McCartney

Senior Director, Product Leadership
Brian Austad

Brian Austad

Vice President, Head of Pharmaceutical Sciences
Dilara McCauley

Dilara McCauley

Vice President, Product Leadership

Karyopharm Therapeutics Office Locations

Karyopharm Therapeutics has offices in Newton and München
Newton, US (HQ)
85 Wells Ave
München, DE
9 Franziska-Bilek-Weg
Show all (2)
Report incorrect company information

Karyopharm Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2008

Total Funding

$248.7 m

Investors

Karyopharm Therapeutics is a subsidiary of Biogen

Karyopharm Therapeutics Financials

Karyopharm Therapeutics's revenue was reported to be $250 k in FY, 2015 which is a 9.2% increase from the previous period.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

387 k229 k250 k

Revenue growth, %

(41%)9%

General and administrative expense

5.9 m15.9 m21.6 m23.9 m

R&D expense

28.5 m60.1 m97.7 m86.9 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

General and administrative expense

2.9 m3.3 m3.8 m5.4 m6.2 m4.8 m5.6 m6 m5.9 m6.3 m6.6 m5.8 m

R&D expense

11 m13.2 m16 m20.8 m27 m25.9 m21.8 m24.6 m19.9 m24.1 m23.1 m25.2 m

Operating expense total

13.9 m16.5 m19.8 m26.2 m33.2 m30.7 m27.3 m30.5 m25.8 m30.3 m29.8 m31.1 m

EBIT

(13.7 m)(16.4 m)(19.7 m)(26.2 m)(33 m)(30.6 m)(27.3 m)(30.5 m)(25.7 m)(30.3 m)(29.8 m)(31.1 m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

156 m150.6 m58.4 m49.7 m

Inventories

2 m2 m2 m2.1 m

Current Assets

158 m207.8 m177.6 m131.6 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

144.9 m132.3 m227.1 m51.5 m24.2 m43.5 m42.2 m37.7 m43.9 m25.6 m55.4 m54.5 m

Current Assets

147.6 m135.3 m231.3 m249.3 m225.3 m198.3 m138.1 m124.2 m130.3 m112.2 m145.7 m121.7 m

PP&E

322 k604 k2.7 m3.3 m3.2 m3.7 m3.3 m3.2 m3 m2.7 m2.5 m2.3 m

Total Assets

149.3 m137.7 m235.2 m292 m263.3 m237 m192.1 m170.9 m183.6 m155.4 m185.8 m163.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(33.9 m)(75.8 m)(118.2 m)(109.6 m)

Depreciation and Amortization

144 k323 k634 k717 k

Inventories

(1.4 m)(45 k)(55 k)(120 k)

Accounts Payable

664 k4.5 m(2.4 m)945 k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(13.7 m)(16.4 m)(19.7 m)(26.1 m)(32.7 m)(30.4 m)(27.1 m)(30.2 m)(25.4 m)(29.9 m)

Accounts Payable

3.5 m2.1 m7 m4.5 m4.6 m4.1 m4.1 m2.2 m4.2 m
Show all financial metrics

Karyopharm Therapeutics Operating Metrics

FY, 2015

Patents Issued

10
Show all operating metrics
Report incorrect company information